Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | BCHE | P06276 | 3/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200951 | 1.00 | FDPS (0.47) | FDPSCA12CA1CA2CA7 | |
| SCHEMBL13953920 | 0.90 | TSHR (0.46) | FDPSCA12CA1CA2CA7 | |
| SCHEMBL201640 | 0.86 | FDPS (0.44) | FDPSCA12CA1CA2CA7 | |
| SCHEMBL201639 | 0.86 | FDPS (0.44) | FDPSCA12CA1CA2CA7 | |
| SCHEMBL200763 | 0.85 | TDP1 (0.46) | TDP1MEN1KMT2ACYSLTR2CYSLTR1 | |
| SCHEMBL2683950 | 0.81 | ALDH1A1 (0.40) | FDPSCA12CA1CA2CA7 | |
| SCHEMBL2685070 | 0.80 | FDPS (0.41) | FDPSCA12CA1CA2CA7 | |
| SCHEMBL201784 | 0.80 | MEN1 (0.59) | TDP1MEN1KMT2AALOX5SMN1; SMN2 | |
| SCHEMBL29213722 | 0.79 | TDP1 (0.64) | TDP1MEN1KMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL13690226 | 0.77 | DHFR (0.42) | MEN1KMT2ACYSLTR2CYSLTR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411358-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-8093253-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093253-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093253-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
| WO-2009077385-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077385-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009024492-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024492-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | FDPS 148/4885CA12 4223/4885CA1 4515/4885 |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | LTB4R2, LTB4R, LTC4S | FDPS 148/4885CA12 4223/4885CA1 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.